Cargando…
Talactoferrin Immunotherapy in Metastatic Renal Cell Carcinoma: A Case Series of Four Long-Term Survivors
Talactoferrin alfa (also known as recombinant human lactoferrin, rhLF) is a novel immunomodulatory protein that has previously demonstrated anti-tumor properties in animal models. Following a successful phase I trial, it was administered orally to patients with metastatic renal cell carcinoma (RCC)...
Autores principales: | Lewis, Mark A., Hayes, Teresa G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194025/ https://www.ncbi.nlm.nih.gov/pubmed/22043271 http://dx.doi.org/10.4021/jocmr499w |
Ejemplares similares
-
Long-Term Survivors with Metastatic Uveal Melanoma
por: Buzzacco, Dominic M, et al.
Publicado: (2012) -
Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017) -
Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype
por: VATU, BOGDAN IONEL, et al.
Publicado: (2020) -
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2020) -
Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)